Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewTocriscreen Kinase Inhibitor 3.0 compound library is a collection of 210 kinase inhibitors supplied pre-dissolved in DMSO (100 μL 10 mM solution). The Tocriscreen Kinase Inhibitor 3.0 Library contains compounds targeting >60 different kinases, including extensive coverage of well-established targets such as VEFGR and AKT, as well as novel targets such as Haspin and DYRK. The Tocriscreen Kinase Inhibitor 3.0 library is suitable for high-throughput screening (HTS), cell based high-content screening (HCS), target validation and assay development. Please view the kinase tree image for a closer look at the pharmacological diversity of this compound library.
If this library does not suit your needs, please submit your requirements through our Tocriscreen PRO custom compound library service.
Kinase phylogenetic tree illustrating the pharmacological diversity of the Tocriscreen Kinase Inhibitor 3.0 Library. The 210 compounds in the Tocriscreen Kinase Inhibitor 3.0 compound library target over 230 kinases. Targets are evenly spread across all the major IUPHAR kinase subfamilies, with a mix of well-established targets such as VEFGR and AKT, and “dark” kinases such as CDK19 and DYRK1B. To view a larger PDF version of this image, please click on the 'kinase tree' link in the product description.
Chemical diversity of the Tocriscreen Kinase Inhibitor 3.0 compound library. The images show the overlapping chemical space of the 210 compounds in the Tocriscreen Kinase Inhibitor 3.0 compound library (green dots) in relation to the chemical space occupied by the ChEMBL kinase inhibitors (grey dots). Each dot represents a unique fingerprint generated from each compound's 3D molecular structure. The even distribution of the fingerprints of the compounds in the Tocriscreen Kinase Inhibitor 3.0 compound library highlights the chemical diversity of this library.
Major IUPHAR kinase subfamilies covered by Tocriscreen Kinase Inhibitor 3.0 Library. TK (tyrosine kinase, 29%); CMGC (includes CDK, MAPK, GSK3 and CLK families, 19%); TKL (tyrosine kinase-like, 16%); AGC (includes PKA, PKG and PKC families, 11%); Atypical (7%); CAMK, (calcium/calmodulin-dependent protein kinases, 4%) and Other Kinases (includes CAMKK, CK1 and STE, 14%).
To request a list of the compounds available in the Tocriscreen Kinase Inhibitor 3.0 please click the request tile below. Compound lists can be provided in Excel or SD format.
Storage | Store at -20°C |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
If you know of a relevant reference for Tocriscreen Kinase Inhibitor 3.0, please let us know.
Keywords: Tocriscreen Kinase Inhibitor 3.0, Tocriscreen Kinase Inhibitor 3.0 supplier, tocriscreen, kinase, inhibitor, library, kinases, toolbox, inhibitors, inhibits, compound, libraries, high-throughput, screening, high-content, chemical, biology, applications, Tocriscreen, Compound, Libraries, 7844, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for Tocriscreen Kinase Inhibitor 3.0 include:
Lee et al (2021) A screen of kinase inhibitors reveals a potential role of Chk1 in regulating Hydra head regeneration and maintenance. Int J Dev Biol 65 523 PMID: 34549798
Jacoby et al (2018) Protocols for the design of kinase-focused compound libraries. Mol.Inform. 37 e1700119 PMID: 29116686
Gilles et al (2021) Developments in the discovery and design of protein kinase D inhibitors. Chem.Med.Chem. 16 2158 PMID: 33829655
Wang et al (2019) EGFR-Aurka signaling rescues polarity and regeneration defects in dystrophin-deficient muscle stem cells by increasing asymmetric divisions. Cell Stem Cell 24 419 PMID: 30713094
Moret et al (2019) Cheminformatics tools for analyzing and designing optimized small-molecule collections and libraries. Cell Chem Biol 26 765 PMID: 30956147
Chaudhari et al (2019) Transient c-Src Suppression During Endodermal Commitment of Human Induced Pluripotent Stem Cells Results in Abnormal Profibrotic Cholangiocyte-Like Cells. Stem Cells 37 306 PMID: 30471152
Yang et al (2019) NTRK1 is a positive regulator of YAP oncogenic function. Oncogene 38 2778 PMID: 30542115
Azad et al (2018) A LATS biosensor screen identifies VEGFR as a regulator of the Hippo pathway in angiogenesis. Nat Commun 9 1061 PMID: 29535383
Moeschler et al (2018) 1-Benzyl-3-cetyl-2-methylimidazolium Iodide (NH125) Is a Broad-Spectrum Inhibitor of Virus Entry with Lysosomotropic Features. Viruses 10 E306 PMID: 29874821
Tomilov et al (2018) Idebenone is a cytoprotective insulin sensitizer whose mechanism is Shc inhibition. Pharmacol Res 137 89 PMID: 30290222
Markussen et al (2018) GSK3 is a negative regulator of the thermogenic program in brown adipocytes. Sci.Rep. 8 3469 PMID: 29472592
Gull et al (2022) Screening of chemical libraries using xenopus embryos and tadpoles for phenotypic drug discovery. Cold Spring Harb.Protoc. 4 PMID: 36180216
Carlson et al (2022) Discovery and characterization of multiple classes of human CatSper blockers. Chem Med Chem 17 e202000499 PMID: 35644882
Haga et al (2024) Positive and negative feedback regulation of the TGF-β1 explains two equilibrium states in skin aging. iScience 27 109708 PMID: 38706856
Mudaliar et al (2024) Discovery of a CK2α'-biased ATP-competitive inhibitor from a high-throughput screen of an allosteric-inhibitor-like compound library. ACS Chem.Neurosci. PMID: 38908003
Orlando et al (2023) Chemical genomics reveals targetable programs of human cancers rooted in pluripotency. Cell Chem.Biol. 30 780 PMID: 37379846
Hewage et al (2020) Chemical manipulation of abscisic acid signaling: a new approach to abiotic and biotic stress management in agriculture. Adv.Sci. 7 2001265 PMID: 32999840
Do you know of a great paper that uses Tocriscreen Kinase Inhibitor 3.0 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review Tocriscreen Kinase Inhibitor 3.0 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image